Yabao gets Chinese license to Lilly's SGLT1 program

Yabao Pharmaceutical Group Co. Ltd. (Shanghai:600351) partnered with Eli Lilly and Co. (NYSE:LLY) to co-develop a sodium-glucose cotransporter 1 ( SGLT1) inhibitor to treat diabetes. Yabao said the program has completed a Phase I study in Singapore; President of R&D Peng Wang declined to name the candidate. Financial terms were undisclosed.

Yabao will receive Chinese development and commercialization rights to the compound, while Lilly will retain rights elsewhere. The companies will jointly determine a development plan for China. Yabao will perform and fund initial development, while Lilly will have buy-in options for China rights. ...